Madison-based Exact Sciences Corporation is revolutionizing the world of cancer screening and diagnostic test products, not only in the United States but across the globe. The company's flagship product, Cologuard, is a non-invasive, stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. But that's not all - Exact Sciences also offers a range of other diagnostic tests, including the Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test for tumor profiling, and Covid-19 testing services. With a focus on enhancing the performance characteristics of the Cologuard test and developing blood and other fluid-based tests, Exact Sciences is a highly innovative player in the cancer diagnostic space. The company has license agreements with MAYO Foundation for Medical Education and Research and Hologic, Inc. With its impressive array of cutting-edge products and services, Exact Sciences is leading the way in the fight against cancer.
Exact Sciences's ticker is EXAS
The company's shares trade on the NASDAQ stock exchange
They are based in Madison, Wisconsin
There are 1001-5000 employees working at Exact Sciences
It is exactsciences.com
Exact Sciences is in the Healthcare sector
Exact Sciences is in the Biotechnology industry
The following five companies are Exact Sciences's industry peers: